Geburtshilfe und Frauenheilkunde · 2018 · 35 citations · 33 references
MedicineOncologySurgeryEndocrine OncologyGynecologic OncologySurgical OncologyGynecologic Oncology SurgeryGynecologic PathologyHormonal Cancer TherapyOvarian CancerOvarian NeoplasiaTumor GradingLow-grade Serous CarcinomaOvarian Cancer Clinical TrialsOvarian Cancer Hormonal TherapyOvarian Cancer TreatmentOvarian Tumor GradingSerous NeoplasmsSerous Ovarian TumorsTwo-tier Grading
In the early 2000s a two-tier grading system was introduced for serous ovarian cancer. Since then, we have increasingly come to accept that low-grade serous ovarian carcinoma (LGSOC) is a separate entity with a unique mutational landscape and clinical behaviour. As less than 10% of serous carcinomas of the ovary are low-grade, they are present in only a small number of patients in clinical trials for ovarian cancer. Therefore the current treatment of LGSOC is based on smaller trials, retrospective series, and subgroup analysis of large clinical trials on ovarian cancer. Surgery plays a major role in the treatment of patients with LGSOC. In the systemic treatment of LGSOC, hormonal treatment and targeted therapies seem to play an important role.
33
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · New England Journal of Medicine · 2016 · 2.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +15
Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations
Pharmacy, Oncology, Pharmacotherapy +14
Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text
Medicine, Gynecology, Oncology +12